...
首页> 外文期刊>Regulatory Toxicology and Pharmacology: RTP >A human relevance investigation of PPAR alpha-mediated key events in the hepatocarcinogenic mode of action of propaquizafop in rats
【24h】

A human relevance investigation of PPAR alpha-mediated key events in the hepatocarcinogenic mode of action of propaquizafop in rats

机译:PPARα介导的大鼠肝癌的肝癌作用模式中PPARα介导关键事件的人文相关性研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Propaquizafop is an herbicide with demonstrated hepatocarcinogenic activity in rodents. A rodent-specific mode of action (MOA) in the liver via activation of peroxisome proliferator-activated receptor alpha (PPAR alpha) has been postulated based on existing data. Experience with PPAR alpha-inducing pharmaceuticals indicates a lack of human relevance of this MOA. The objective of the present investigation was to evaluate the dependency of early key events leading to liver tumors on PPAR alpha activation in wildtype (WT) compared to PPAR alpha-knockout (KO) rats following 2 weeks exposure to 75, 500 and 1000 ppm propaquizafop in the diet. In WT rats, both WY-14643 (50 mg/kg bw/day) and propaquizafop (dose-dependently) induced marked increases in liver weights, correlating with liver enlargement and hepatocellular hypertrophy, along with increased CYP4A and acyl-CoA oxidase mRNA expression and enzyme activities versus controls, while in KO rats liver weight was mildly increased only at the high dose with minimal microscopic correlates and without any changes in liver peroxisomal or CYP4A activities. In addition, BrdU labeling resulted in higher numbers and density of positive hepatocytes versus controls in WT but not in KO rats, indicating increased mitotic activity and cell proliferation only in WT rats, thus confirming the PPAR alpha-dependency of the biochemical and histological changes in the liver. Based on an assessment of the results of this investigation, together with existing propaquizafop data according to the MOA-Human Relevance Framework, we conclude that liver tumors observed in rodents after dietary administration of propaquizafop do not pose a relevant health risk to humans.
机译:ProPaquizaFop是一种除草剂,具有啮齿动物的肝癌活性。通过激活过氧化物体增殖物激活的受体α(PPAR alpha)的肝脏特异性作用(MOA)是基于现有数据假设的。 PPARα-诱导药物的经验表明了这款MOA的人类相关性。本研究的目的是评估早期关键事件导致肝脏肿瘤对PPARα激活的依赖性与在2周暴露于75,500和1000ppm的PPARα-kexpla-kexpout(KO)大鼠相比野生型(WT)中的PPARα激活在饮食中。在WT大鼠中,WY-14643(50mg / kg BW /天)和丙曲线(剂量依赖性)诱导肝脏重量的显着增加,与肝增大和肝细胞肥大相关,以及增加的CYP4A和酰基-CoA氧化酶mRNA表达和酶活性与对照组,而在KO大鼠肝脏重量中仅在高剂量下轻微增加,具有最小的显微镜相关,并且没有肝脏过氧硅运动或CYP4A活性的任何变化。此外,Brdu标记导致WT中的阳性肝细胞的数量和密度较高,但不在KO大鼠中,表明仅在WT大鼠中增加了有丝分裂活性和细胞增殖,从而证实了生物化学和组织学变化的PPARα依赖性肝脏。基于对该调查结果的评估,根据MoA-Lubs-Hervercancy框架的结果,我们得出结论,在膳食给予Propaquizafop饮食管理后,在啮齿动物中观察到肝脏肿瘤对人类没有对人类产生相关的健康风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号